MYL9 ANTIBODY Russian patent published in 2021 - IPC C07K16/18 A61K39/395 A61P1/00 A61P11/00 A61P35/00 A61P37/08 

FIELD: pharmaceuticals.

SUBSTANCE: group of inventions refers to an antibody to the myosin regulatory light chain (Myl)9 polypeptide or its Myl9-binding fragment and use thereof. Disclosed is an antibody to Myl9 or its Myl9-binding fragment containing (a) a heavy chain CDR1 consisting of a peptide represented by the amino acid sequence SEQ ID NO: 28, (b) a heavy chain CDR2 consisting of a peptide represented by the amino acid sequence SEQ ID NO: 30, (c) a heavy chain CDR3 consisting of a peptide represented by the amino acid sequence SEQ ID NO: 32, (d) a light chain CDR1 consisting of a peptide represented by the amino acid sequence SEQ ID NO: 33, (e) light chain CDR2, consisting of a peptide represented by amino acid sequence SEQ ID NO: 34 and (f) CDR3 light chain consisting of a peptide represented by amino acid sequence SEQ ID NO: 35. There are also presented versions of the antibody to Myl9 or its Myl9-binding fragment, isolated nucleic acid coding antibody to Myl9 or its Myl9-binding fragment, an expression vector comprising said nucleic acid, a host cell for producing said antibody or its Myl9-binding fragment, comprising a vector, method of producing said antibody or its Myl9-binding fragment, as well as a pharmaceutical composition containing a therapeutically effective amount of the antibody or its Myl9-binding fragment.

EFFECT: invention enables to inhibit the interaction between Myl9 and CD69.

25 cl, 16 dwg, 1 tbl, 7 ex